As previously mentioned, CD52 knockdown resulted in significant reductions in ATP, lactate, and glucose levels in NSCLC cells (p < 0.01), which were partially restored after AKT treatment (p < 0.01) (Fig. 4F-4G). The gene discussed is CD52; the disease is non-small cell lung carcinoma.